ADVERTISEMENT
Abstract
ARRY-520 demonstrated clinical activity in a Phase 1 dose-escalation study that warranted further exploration of activity in a Phase 2 study.
ADVERTISEMENT
Related articles
Poster
non-peer-reviewed
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Author Information
Array BioPharma Corresponding Author
Not Selected
Poster Information
Publication history
Published: September 17, 2012
Copyright
© Copyright 2012
BioPharma. This is an open access poster distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License
This is an open access poster distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.